Bisphosphonate Preparations Currently Available in the US

 

 

Primary
Indication

Nitrogen
Containing

Dose

Route

Relative
Potency**

Etidronate
(Didronel)

Paget’s
Disease

No

300-750
mg daily for
6 months

Oral

1

Tiludronate
(Skelid)

Paget’s
Disease

No

400 mg
daily for 3
months

Oral

50

Alendronate
(Fosamax)

Osteoporosis

Yes

10 mg/day
70 mg/week

Oral

1,000

Risedronate
(Actonel)

Osteoporosis

Yes

5 mg/day
35 mg/week

Oral

1,000

Ibandronate
(Boniva)

Osteoporosis

Yes

2.5 mg/day
150
mg/month

Oral

1,000

Pamidronate
(Aredia)

Bone
Metastasis

Yes

90 mg/3
weeks

IV

1,000 –
5,000

Zoledronate
(Zometa)

Bone
Metastasis

Yes

4 mg/3
weeks

IV

10,000 +

 

*A once-yearly infusion of zoledronic acid for the treatment of postmenopausal osteoporosis is under FDA review.
**Relative to etidronate